Focal Segmental Glomerulosclerosis (FSGS) Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Focal Segmental Glomerulosclerosis (FSGS) Treatment Market is Segmented by Disease Type (Primary FSGS, Secondary FSGS), Disease Management, and Geography

Market Snapshot

Focal Segmental Glomerulosclerosis Treatment Market Size
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 7.5 %
Focal Segmental Glomerulosclerosis Treatment Market Major Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Focal Segmental Glomerulosclerosis (FSGS) Treatment Market is primarily driven by the increasing disease burden, rising focus towards rare diseases, and increasing R&D activity. It has been found that in comparison to other glomerular diseases, the prevalence of FSGS is growing fast worldwide. 

As per the NephCure, each year, there are about more than 5,400 patients that are being diagnosed with FSGS and about 20,000 patients with ESRD were earlier affected due to FSGS. In addition, people of African ancestry have five times higher diagnosis rate, and those who do not respond to the steroids move for kidney transplant or dialysis, wherein 30%-40% of patients, the FSGS disease recurs. Further, as per the University of California, the ESRD is increasing by 5% each year. With that, the need for donor's kidneys is rising by 8% each year. 

Both developed and emerging markets are going through increasing demand for the kidney transplants and a higher rate of hospitalizations, due to kidney malfunction. This increases the demand to diagnose the initial stage of FSGS diseases during the treatment of kidney diseases. Thus, the burden of glomerulus-related disorders drives the demand for the FSGS market over the forecast period.

Scope of the Report

As per the scope of the report, the focal segmental glomerulosclerosis is the progressive scarring of the kidney, which is characterized by proteinuria. It is among the rare diseases, which affects kidney function by attacking and damaging the glomeruli. This disease is characterized by kidney defects by birth, obesity, obstructive sleep apnea, sickle cell anemia, viruses, such as HIV, among others.

By Disease Type
Primary FSGS
Secondary FSGS
By Disease Management
Diagnosis
Kidney Biopsy
Creatinine Test
Other Diagnoses
Treatment
Drug Therapy
Dialysis
Kidney Transplant
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Primary FSGS is Expected to Register a High CAGR in the Disease Type Segment

Primary FSGS has become one of the most common causes of idiopathic glomerular disease in adults. The primary FSGS is usually “idiopathic,” referring to rise of disease without any known, definite or apparent reason. It has several prototypical characteristics and is the most common form in adolescents and young adults. The current therapy for the primary FSGS includes immunosuppressive agents, such as glucocorticoids and calcineurin inhibitors. Steroid therapy is among the most basic and standard treatment with oral prednisone. Some of the major emerging companies having their potential drug candidates in the pipeline are Chemocentryx, Reata, Pharmaceuticals, Retrophin Inc., and Vertex Pharmaceuticals.

Since it is a rare disease, specialty clinical-stage companies are likely to get more funds and are leveraging the strategic partnership opportunities. Moreover, the companies are directing their R&D efforts toward more targeted therapies as a solution to traditional drug and surgical treatments. Hence, owing to the above-mentioned statements, it has been observed that the segment will have rapid growth over the forecast period.

Focal Segmental Glomerulosclerosis Treatment Market Share

North America is Expected to Have the Largest Share in the FSGS Treatment Market

North America accounts for a leading share in the market because of the presence of a properly structured health care industry and availability of reimbursement policies with wider coverage. There is an increasing prevalence of FSGS, the presence of state-of-the-art healthcare infrastructure, the high adoption rate of new healthcare technology, and presence of reimbursements are facilitating the market growth.

Moreover, the United States is among the first choice for several manufacturers to conduct clinical trials. Majority of FSGS clinical trials have happened or are in progress in the United States, with high involvement of universities and research centers involved in the funding of the trials, dominated by drugs under trials. For FSGS, several clinical trials and approvals for clinical trials of drugs are under process, which shows a high growth over the forecast period.

Focal Segmental Glomerulosclerosis Treatment Market Report

Competitive Landscape

The FSGS treatment market is moderately consolidated and consists of the global players that are into the medical devices business that provide products related to dialysis or other diagnostics. The major pharmaceutical companies involved in this market are having their products in the pipeline and are expected to release their products in the coming years.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Burden of Focal Segmental Glomerulosclerosis (FSGS)

      2. 4.2.2 High Focus on Developing New Treatment Options

      3. 4.2.3

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Dialysis and Kidney Transplant

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Disease Type

      1. 5.1.1 Primary FSGS

      2. 5.1.2 Secondary FSGS

    2. 5.2 By Disease Management

      1. 5.2.1 Diagnosis

        1. 5.2.1.1 Kidney Biopsy

        2. 5.2.1.2 Creatinine Test

        3. 5.2.1.3 Other Diagnoses

      2. 5.2.2 Treatment

        1. 5.2.2.1 Drug Therapy

        2. 5.2.2.2 Dialysis

        3. 5.2.2.3 Kidney Transplant

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 B. Braun Melsungen AG

      2. 6.1.2 Beckman Coulter Inc. (Danaher)

      3. 6.1.3 Baxter International Inc.

      4. 6.1.4 ChemoCentryx Inc.

      5. 6.1.5 Complexa Inc.

      6. 6.1.6 Dimerix Ltd

      7. 6.1.7 Medtronic PLC

      8. 6.1.8 Pfizer Inc.

      9. 6.1.9 Retrophin Inc.

      10. 6.1.10 Variant Pharmaceuticals Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Focal Segmental Glomerulosclerosis (FSGS) Treatment Market market is studied from 2018 - 2026.

The Focal Segmental Glomerulosclerosis (FSGS) Treatment Market is growing at a CAGR of 7.5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

B. Braun Melsungen AG, Beckman Coulter Inc. (Danaher Corporation), Medtronic Plc, Retrophin Inc., Complexa Inc. are the major companies operating in Focal Segmental Glomerulosclerosis (FSGS) Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!